Citigroup’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
Citigroup's TARA Position: Q1 2026 in Review
Citigroup reduced its Protara Therapeutics (TARA) stake by 1.5% in Q1 2026, selling an estimated $1.33K and leaving 14,476 shares worth $75.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4379.
Citigroup first reported a position in TARA in Q2 2015 and has held it in 17 quarters since. The position peaked at $78.4K in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- Citigroup held 14,476 shares of Protara Therapeutics worth $75.4K as of Q1 2026.
- Citigroup sold 224 Protara Therapeutics shares in Q1 2026, an estimated $1.33K.
- Protara Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4379 holding.
- Citigroup first reported a position in Protara Therapeutics in Q2 2015 and has held it in 17 quarters since.
- Citigroup's Protara Therapeutics position peaked at $78.4K in Q4 2025.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.